Advances in Alzheimer’s disease research have led to the development of biomarkers that can trace the disease at the biological level since an early phase. Colin L. Masters, MD, Florey Institute of Neuroscience and Mental Health, Parkville, Australia, discusses the latest developments concerning blood and cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease. They are revolutionizing the field as they can trace the disease before the neuroimaging PET signal changes. These biomarkers can greatly improve Alzheimer’s disease detection, which will impact the treatment and prevention of the disease. This interview took place during the AD/PD™ 2021 conference.

свернуть